Trending Now
Free Weekly Newsletter.
We've been publishing our newsletter since 1998, and have had our share of huge winners including Immunomedics (IMMU) $3.00 to $86.00 (2016-2020). So sign up, it's free, and see what else we can come up with!
ALL NEWS
And We Have a Trading Idea!
Adding Zomedica (ZOM, ZOMDF) $0.037 to Watch List.
Our first 'publicly announced' trading idea, in what might be decades. It's from a friend (we'll call him Bob, an old-timer...
We’re Back! And We’re Adding (again), GeoVax (GOVX), the Alkaline Water Co (WTER) and...
GeoVax (GOVX) $1.64. Recent High $11.18 (BiotechStockReview)
The Alkaline Water Co. (WTER) $0.09. Recent High $0.48 (BeverageStockReview)
Society Pass (SOPA) $1.27. Recent High $6.75. (InternetStockReview)
Adding Quantum Pharmaceutical (QNTM) $4.10 to Reverse Split Stock Watch List.
119% Gain Post Split
Subscribe for Upcoming Report
Nine Page Summary Report on GeoVax (GOVX)
This is a great long-term story. We’re telling you.
(March 2024) When we finished writing our earlier 44-page report, we printed it out and we took it...
GeoVax (GOVX) Provides First Half 2024 Business Update.
Award of BARDA Project NextGen contract represents a significant milestone event;
Total value of award to GeoVax and its CRO partner total approximately...
Reverse Split Mania! Solgenix (SNGX) Jumps 448% After 1:16.
Can You Imagine Selling Solgenix at $2.00 yesterday.
And to be honest, news wasn't all that big - such as FDA approval. What the reported was INTERIM DATA from...
GeoVax Receives Massive $300+ Million BARDA Project NextGen Award!
Are we happy, you betcha!
We just got back from St Croix where the team from the Beverage Stock Review visited the Mutiny Island Vodka Distillery to see if...
GeoVax (GOVX) Research Reports Archive
Research Report Archive
Reports from Robert LeBoyer at Noble Capital. Jeffrey Kraws and Karen Goldfarb at Crystal Research. Jason Kolbert at Dawson James Securities. Vernon Bernardino at H.C....
Ardelyx (ARDX) Reports First Quarter 2024 Showing $204 Million in Cash!
When we added Ardelyx (ARDX) to the Watch List in November of 2022, the market cap near $80 million. Now it's approaching $2 billion after some 'dilution,' which didn't prevent it...
GeoVax to Provide Corporate Update on Tuesday May 14, 2024.
Still our favorite biotech microcap, still our favorite management team, and our favorite risk to reward idea with a $4 million market cap, addressing solutions which reach well over $1 billion. ...
NovaVax (NVAX) Roars Higher, Gaining 225% a $1.2 Billion Increase, at the Blink of...
Sanofi (SNY) Announces Partnership - $500 Million Upfront, plus $700 million in Milestones with NovaVax (NVAX). And some investors say Covid is gone - oh Pshaw with them!
Novavax...
COVID-19 Immunity From mRNA Booster Does Not Last Very Long.
Study finds that the median length for the antibody half-life immune response was 63 days for the primary series, and increased to 115 days for those who went on to receive their...
We’re in Tampa for the Kentucky Derby.
GeoVax (GOVX), Sees a Little Volume.
Normally, we get a little nervous when one of the companies we follow, shows a spike in either price or volume while...
Adding Citius Pharma (CTXR) $0.66 to 2024 Watch List.
Three Years Since we Last Added Citius (CTXR) to the Watch List, and it Looks Better Than Ever!
We're adding Citius Pharma to the Watch List, on the...
Citius Pharmaceuticals (CTXR) Prospectus, Powerpoint & Fact Sheet.
CRANFORD, N.J., April 26, 2024 /PRNewswire/ -- Citius Pharmaceuticals Inc. (Nasdaq: CTXR) ("Citius" or the "Company"), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, today announced that it has...
Adding Asia Broadband (AABB) to Speculative Watch List.
Asia Broadband, Gold Play With Digital Currency (NFT) Twist
The last speculative stock trading under $0.05, that we added to the Watch List was Pharamather (PHRRF), which traded...
Trump’s (DJT) up 48% Today
LIVE QUOTE
Our only thought is it would be a great idea, to give some of the stock to E Jean Carroll for her...
Research Report: Society Pass (SOPA) $0.22. Price Target $4.00.
Three New Reports on Society Pass (SOPA) With Price Targets from $3.00 to $4.00.
(All Report Archive)
December 27th, 2023. Litchfield...
LQR House (LQR) Commits to Postpone Public Offerings for the Foreseeable Future.
LQR House Initiates Warrants Cancellation and Commits to Postpone Public Offerings for the Foreseeable Future
MIAMI BEACH, FL / ACCESSWIRE / December 20,...
Continued Strength at LQR House (LQR) Post-Reverse Split.
Like a Surprise Christmas Gift, LQR House has Gained Nearly Four-Fold (330%) Post Split. New Report out Tomorrow.
LIVE QUOTE
And We Have a Trading Idea!
Adding Zomedica (ZOM, ZOMDF) $0.037 to Watch List.
Our first 'publicly announced' trading idea, in what might be decades....
We’re Back! And We’re Adding (again), GeoVax (GOVX), the Alkaline Water Co (WTER) and...
GeoVax (GOVX) $1.64. Recent High $11.18 (BiotechStockReview)
The Alkaline Water Co. (WTER) $0.09. Recent High $0.48 (BeverageStockReview)
Nine Page Summary Report on GeoVax (GOVX)
This is a great long-term story. We’re telling you.
(March 2024) When we finished writing our earlier...
GeoVax (GOVX) Provides First Half 2024 Business Update.
Award of BARDA Project NextGen contract represents a significant milestone event;
Total value...
FDA approves Amgen drug for tough-to-treat form of lung cancer.
Known scientifically as tarlatamab, Indelltra is only for patients once they progress following chemotherapy. On chemotherapy alone, patients can expect...
IPOS
conference calls
Spine Surgery Service Provider Assure Holdings (ARHH) $1.33 Conference Call.
Assure Holdings Sets First Quarter 2019 Conference Call for Wednesday, May 29, 2019, at 11:00 a.m. ET
DENVER, May...
Most popular
Revive Therapeutics Announces Entry Into Phase III FDA Trial Using Glutathione Boosting Bucillamine.
Revive Therapeutics Announces U.S. FDA Recommendation to Proceed Directly Into A Phase 3 Confirmatory Clinical Trial
TORONTO, April...
Seven of the World’s Top Performing Stocks, Every Morning
THE TIKI HUT FUND | MONDAY'S BIGGEST MOVERS
FDA Approves Most Expensive Drug Ever, @ $3.5 Million-Per-Dose, from uniQure (QURE).
Important to note, the FDA didn't approve the price, they approved the drug. It was priced afterwards. Second item it is a...
That’s it. $225 Million Raised by Atai (ATAI) Gets us Interested in the Psychedelics...
Redefining how the world approaches, prevents, and heals mental health disorders.
LIVE QUOTE